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Abstract
Background: Young breast cancer survivors are often dissatisfied with the information provided on fertility and
sexuality. Our aim was to discuss possible contributing factors and to propose strategies to increase patient
satisfaction with such information.
Methods: Using the French National Health Insurance System database, we constituted the ELIPPSE40 regional
cohort of 623 women, aged 18–40, diagnosed with breast cancer between 2005 and 2011. As of January 2014, 319
women had taken part in the 10-, 16-, 28 and 48-month telephone interviews. Satisfaction with the information
provided about the potential impact of cancer and its treatment on fertility and sexuality was assessed at
48 months after diagnosis on 5-point Likert scales.
Results: Four years after diagnosis, only 53.0 and 42.6 % of women were satisfied with fertility- and sexuality-related
information, respectively, without any significant change over the 2009–2014 period (P = 0.585 and P = 0.676
respectively). The two issues were moderately correlated (ρ = 0.60; P <0.001). General satisfaction with medical
follow-up was the only common correlate. Irrespective of sociodemographic and medical characteristics, satisfaction
with fertility-related information was greater among women with a family history of breast/ovarian cancer who had
the opportunity to ask questions at the time of cancer disclosure. Satisfaction with sexuality-related information
increased with the spontaneous provision of information by physicians at cancer disclosure.
Conclusions: Promoting both patients’ question asking behavior and more systematic information could improve
communication between caregivers and young breast cancer survivors and address distinct unmet needs regarding
fertility- and sexuality- related information.
Keywords: Breast cancer, Young women, Satisfaction, Fertility- and sexuality-related information, Prospective cohort,
ELIPPSE40
Background
Thanks to early detection and treatment improvement, the
mortality rate from Breast Cancer (BC) has declined over
the past 20 years [1, 2]. Approximately 91 % of women
with BC now survive for more than 5 years [2], although
the prognosis appears to be worse in young women [3, 4].
Despite improved survival rates, the literature describes a
wide range of difficulties in patients’ day-to-day lives aris-
ing from BC and associated treatment [5–8]. Young BC
survivors face a multitude of challenges, including issues
related to fertility and sexuality, which need to be
addressed.
Among the drugs used in adjuvant therapy for BC,
cyclophosphamide (an alkylating agent) is one of the
most toxic for ovarian function [6, 9, 10]. Common ef-
fects of chemotherapy on ovarian function include tem-
porary or permanent amenorrhea due to premature
ovarian failure. Rates of amenorrhea can reach 80 % in
women under 40 years of age with poor prognosis
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tumors who are prescribed more aggressive regimens,
such as six cycles of fluorouracil plus epirubicin, doxo-
rubicin or methotrexate and cyclophosphamide [6].
After 4–6 cycles of cyclophosphamide containing poly-
chemotherapy, the ovaries of these young women age by
approximately 10 years [10]. In addition, the duration of
initial adjuvant hormone treatment (recommended for
5 years) prevents women from considering pregnancy, as
fertility is likely to be reduced due to age-related decline.
Accordingly, even though young women constitute a mi-
nority of BC patients (each year in France, approxi-
mately 10 % of newly-diagnosed women are under 40,
[11]), they have specific concerns and issues, including
queries regarding fertility.
Although sexual problems decrease over time and
most women regain their previous sexual activity after
treatment [12, 13], women of all ages report more
sexuality-related difficulties (including decreased interest
and sexual desire, anorgasmia, dyspareunia and lower
levels of sexual satisfaction) when compared with their
retrospective pre-diagnosis reports [14–18]. They are
also more concerned about their sexuality than the gen-
eral female population [13, 19, 20]. Sexual dysfunction is
especially prominent among young women who are
more vulnerable to changes in ovarian functioning
resulting from chemotherapy and to concerns about
body image after mastectomy [12, 18, 21, 22]. Sexual
dysfunction is related to psychosocial outcomes, includ-
ing depression, anxiety, and lower quality of life [21–23].
Unfortunately, many young women are not fully aware
or well-informed about the potential adverse effects of BC
treatment on fertility and sexual life [24, 25]. Today, the
possibility of maintaining fertility and re-establishing an
active sex life after cancer means that healthcare providers
must provide adequate information about the effects of
the disease and its treatments [24–26]. Some studies have
shown that a lack of information regarding these issues
can lead to increased patient uncertainty, anxiety, depres-
sion, distress, anger and confusion [27–31]. Conversely,
good communication between patients and healthcare
providers offers many advantages such as a greater satis-
faction with healthcare providers, reduced distress and im-
proved quality of life [24, 30–32]. One study found that
the transmission of clear and complete information (for
illness, medical examinations, treatment, cure, diagnosis,
prognosis and side effects) improved the women’s quality
of life up to 4 years after diagnosis [33]. Similarly, a posi-
tive association was found between satisfaction with infor-
mation obtained and health-related quality of life
dimensions: physical, functional, psychological and social
[34]. Cancer survivors who were satisfied with the infor-
mation provided by the physicians at diagnosis and during
treatment had better mental health and vitality than those
who were not satisfied with the information [35].
In France, the 1st and 2nd national cancer plans [36]
have helped to standardize cancer diagnosis disclosure
by healthcare providers and to improve patient infor-
mation. However, unlike other industrialized nations
[24, 25, 28, 37], French national guidelines regarding
discussions and referral for fertility and sexual health in
the oncology clinics are new, and have not been fully
implemented [38, 39]. Their systematic adoption will
not only ensure the provision of high quality informa-
tion and the coordination of care, but will also prevent
patients from being given conflicting advice about man-
agement of their symptoms. The 3rd French National
Cancer Plan (in February 2014) provides specific rec-
ommendations about the management of infertility
problems, but nothing about sexual issues.
In the context of the national effort to improve the
quality and quantity of information provided after cancer
diagnosis, the aims of the present study were to measure
satisfaction with information provided on the topics of
fertility and sexuality among young women with BC, to
highlight factors contributing to this satisfaction and to
propose possible strategies to increase it.
Methods
Study population
The Longitudinal Study on Psychosocial Impact of
Breast Disease among women under 40 years
(ELIPPSE40 cohort) is an ongoing regional observational
study, first implemented in South Eastern France (PACA
and Corsica regions) in September 2005, which docu-
ments the medium- and long-term consequences of BC
and its treatments on women’s daily and social lives
[40–43]. The study area covers a population of approxi-
mately five million inhabitants. All women with a diag-
nosis of biopsy-proven primary BC, aged 18–40, living
in Southeastern France with a valid address, and in-
cluded in the long-term disease registry of the French
National Health Insurance Fund (NHIF) between 2005
and 2011 were eligible. Study inclusion ended in 2011.
The NHIF database has been extensively used for re-
search purposes and is described in detail elsewhere
[44]. It includes the four major health insurance schemes
(for salaried workers, farmers, professional soldiers and
self-employed workers) and covers 98 % of the French
population. Women with distant metastasis at diagnosis,
cancer relapse, serious cognitive troubles, deafness, or
acute psychiatric disease, and those unable to answer a
questionnaire were not included. The study method-
ology was designed and performed in accordance with
the Declaration of Helsinki, and was approved by two
French national ethics commissions: the CCTIRS
(Comité Consultatif sur le Traitement de l'Information
en Matière de Recherche dans le Domaine de la Santé,
study registered under n°05.254) and the CNIL (French
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Commission on Individual Data Protection and Public
Liberties, study registered under n°05-1319).
Data collection
An additional file shows the questions used in the ana-
lysis, extracted from the ELIPPSE40 cohort question-
naires [see Additional file 1].
Patient questionnaire
An explanatory letter about ELIPPSE40 was sent to all
eligible patients (Fig. 1). Those who provided their
signed written consent to participate were then mailed a
first short self-administered questionnaire (directly after
diagnosis, entitled M0) which included questions on
sociodemographic characteristics and the circumstances
of their BC diagnosis. This short questionnaire was filled
in by the patients in the weeks following their diagnosis
and before they initiated cancer treatment.
Overall perception of the cancer disclosure process
The first short questionnaire (at M0) included items about
patient perception of the overall cancer disclosure process
(Fig. 2a) coming from previous research [41, 42, 45, 46]. A
first question asked patients if they were able to ask all the
questions they wanted at the moment of disclosure. The
answers were given on a 4-point Likert scale that was di-
chotomized secondarily to describe the number of partici-
pants who responded "Yes absolutely" or "Yes maybe"
(versus "No not really" or "No not at all"). A second ques-
tion asked about whether they had received information
about their disease or not. Two other questions asked pa-
tients if the information provided was understandable and
meet their expectations. These 4-point Likert scales with
responses ranging from "Yes absolutely" to "No not at all"
were merged and patients were considered satisfied with
information provided about their disease if they responded
"Yes absolutely" or "Yes maybe" to both questions.
Psychometric measures
Four Computer-Assisted Telephone Interviews (CATI,
conducted by a trained investigator) were planned at 10,
16, 28 and 48 Months after diagnosis (entitled M10,
M16, M28 and M48, respectively).
The initial mental adjustment of women after disclos-
ure of cancer diagnosis was measured at M10 using the
21-item validated French version of the Mental Adjust-
ment to Cancer scale (MAC-21, [47]). The MAC-21
consists of three subscales: “fighting spirit” measures
positive adjustment, while “helplessness/hopelessness”
and “anxious preoccupation” measure negative adjust-
ment [47]. Anxious preoccupation reflects significant
anxiety associated with diagnosis and prognosis, the lat-
ter being perceived as uncertain.
Other validated psychometric scales were also used to
measure quality of life (WHOQOL-BREF, [48]) and de-
pressive symptoms (CES-D, [49]) at all four follow-up
Assessed for eligibility to ELIPPSE40 
cohort (n=1043) 
Ineligible  
   - Inclusion criteria not met (n=92, mostly due to metastasis at diagnosis) 
   - Deceased (n=8) 
  - Unable to contact (n=37)
Eligible 
(n=906) 
- Did not agree to participate (n=283 / 31.2%) 
Answered the mailed self-administered 
questionnaire at enrollment 
(n=623 / 68.8%)
Unavailable 48 months follow-up (n=304) 
   - Had not yet reached the required 4 years of follow-up (n=142 / 22.8%) 
   - Deceases (n=19 / 3.0%) 
   - Lost to follow-up or refusal to participate further (n=143 / 23.0%) 
Study sample 
(n=319) 
Fig. 1 Participant flow chart
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interviews, body image (BIS, [50]) at the last three inter-
views, and sexual dysfunction (Relationship and Sexual-
ity Scale (RSS), [16]) at the final interview (M48) only.
Satisfaction with fertility- and sexuality-related information
(FRI/SRI)
Satisfaction was assessed at M48 on 5-point Likert scales
with responses ranging from "strongly disagree" to
"strongly agree”. The first item of the RSS (“I think I
have received sufficient information about how disease
and treatment (including surgery) might affect my sexual
life”) validated by Berglund et al. [16] was chosen to
measure satisfaction with Sexuality-Related Information
(SRI). It was then adapted (“I think I have received suffi-
cient information about how treatment (including sur-
gery) might affect my fertility”) to measure satisfaction
with Fertility-Related Information (FRI). Women who
answered “I agree” or “I strongly agree” to each question
were considered satisfied with FRI or SRI.
Medical characteristics
In parallel with patients’ telephone interviews, a first med-
ical questionnaire (at M10) was completed by the patient’s
physician who made the diagnoses and/or was in charge
of cancer treatment. This questionnaire dealt with the pa-
tient’s medical history, comorbidities (from the Charlson
index [51]), pathological assessment of BC (date of
diagnosis, tumor size and grade, histological type, lymph
nodes' status, estrogen and progesterone receptor status,
and HER2⁄neu over expression), and information about
treatment. We also collected financial reimbursement data
for hormone therapy drugs. Overall, 99.4 % of patients
had a complete medical questionnaire at M10. For the
two other patients (0.6 %), missing medical information
was completed with the help of subsequent medical ques-
tionnaires and financial reimbursement data.
Statistical analysis
A Spearman’s correlation analysis was performed between
FRI and SRI satisfaction, and depressive symptoms, body
image and other psychosocial characteristics. Chi-squared
tests (categorical characteristics) and Student's t-tests
(continuous characteristics) were used to compare satis-
fied women with the rest of the sample. The associations
between satisfaction and explanatory variables (included
those just listed) were then evaluated using binary logistic
regression models. All variables with a p-value (P) <0.20
in univariate analysis were eligible for the multivariate
model. Systematic adjustment was performed for age, edu-
cational level, parenthood before diagnosis, specific conse-
quences of cancer and its treatment (infertility or sexual
dysfunction) and general satisfaction with medical follow-
up at M48. Multivariate models were estimated after ap-
plying multiple imputation to the 19 (6.0 %) patients who
a)
b)
Fig. 2 Evolution over 5 years of diagnosis of a) patient perception of the overall cancer disclosure process and b) patient satisfaction with
fertility- and sexuality-related information
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had monotone-missing values for educational level, who
were parents before diagnosis and had a history of atten-
tion and/or memory problems (Table 1). Factors associ-
ated with satisfaction were identified in the multivariate
binary logistic regression model using a backward proced-
ure (P <0.10). All analyses were performed using Stata
software (Stata Corp., College Station, Texas, USA).
Results
Description of the study population
From 2005 to 2011, of the 1043 women with BC under 40
identified in the NHIF database, 906 were eligible to par-
ticipate in the ELIPPSE40 cohort (Fig. 1). Among the latter,
283 (31.2 %) did not wish to participate and so 623 were
included. No differences were observed in NHIF character-
istics between those included and those who refused to
participate in terms of age (P = 0.692) size (P = 0.509) and
type (P = 0.501) of municipality, and administrative area
(department) of residence (P = 0.181). As of 27 January
2014, 22.8 % had not yet completed the required 4 years
(M48) of follow-up (therefore 2009 was the last full year
which could be analyzed), 3.0 % were deceased and 23.0 %
were lost to follow-up (or had interrupted their follow-up).
Thus, analysis of FRI and SRI satisfaction was conducted
among the remaining 319 women (Fig. 1). No differences
were observed between these 319 women and those lost to
follow-up (n = 143) in terms of age (P = 0.947), sociodemo-
graphic characteristics and tumor stage (P = 0.193). Over-
all, the comparison between these 319 women and all
those without any 48 months follow-up (n = 304) in term
of age, sociodemographic characteristics and tumor stage
did not reach statistical significance. Patient characteristics
for the 319 women still being followed 4 years after diagno-
sis are described in Table 1. Patients were followed by can-
cer specialist (93.7 %), Obstetrician Gynecologists (61.1 %),
Psychologist/Psychiatrist (59.2 %), and/or primary care
practitioners (43.9 %) over the 4 years. These consultations
with different medical specialties were not statistically asso-
ciated with FRI and SRI satisfaction.
Patient perceived provision of information
Figure 2a shows the evolution of patient perception of
cancer-related information provided at disclosure over
the 2005–2009 period. The levels of information pro-
vided appeared to increase with each year of diagnosis
(P = 0.003) rising from 60.3 % in 2005 to 88.2 % in 2009.
Satisfaction with information provided at diagnosis also
increased (P = 0.011): 52.4 % of women in 2005 reported
that information received met their expectations. This
value rose to 70.6 % in 2009. Patients’ perception about
the ease of asking doctors all the questions they wished
to ask was already high in 2005 and did not significantly
increase over time (P = 0.350).
Four years after diagnosis, only 53.0 and 42.6 % of
women declared that they were satisfied with information
received about fertility and sexuality after cancer, respect-
ively. A moderate correlation (Spearman’s rho (ρ) = 0.60;
P <0.001) was found between these two types of informa-
tion. Their correlates were different: only FRI satisfaction
was associated with women’s overall perception of their
health (ρ = 0.17; P = 0.003) and depressive symptoms (ρ =
−0.15; P = 0.007). Deterioration of body image was signifi-
cantly associated with both FRI satisfaction (ρ = −0.16;
P = 0.004) and SRI satisfaction (ρ = −0.12; P = 0.031).
Finally (Fig. 2b), no significant association was observed
between year of diagnosis and FRI satisfaction (P = 0.585)
or SRI satisfaction (P = 0.676).
Factors associated with satisfaction with fertility-related
information (FRI)
In multivariate analysis (Table 2), factors associated with
lower probability of FRI satisfaction included anxious
preoccupation (MAC-21 subscale). Women who re-
ported that they had had the opportunity to ask all the
questions they wished at cancer disclosure, those who
reported they were satisfied in general with their medical
follow-up, and finally those with a family history of
breast or ovarian cancer, were all more likely to be satis-
fied with FRI than other women.
Factors associated with satisfaction with sexuality-related
information (SRI)
Multivariate analysis showed that a higher level of edu-
cation, a history of attention and/or memory problems
and a lack of general BC information being provided at
cancer disclosure were all independently and negatively
associated with SRI satisfaction. By contrast, women
who reported that they were very satisfied in general
with their medical follow-up were more likely to be sat-
isfied with SRI than others.
Discussion
In this population of young BC survivors, only 53.0 and
42.6 % reported being satisfied with information pro-
vided about fertility and sexuality, respectively, 4 years
after diagnosis. Despite a trend towards a general in-
crease in and satisfaction with the information provided
at cancer disclosure, these two long-term issues, particu-
larly sexuality, remain insufficiently addressed. To our
knowledge, this is the first prospective cohort study to
simultaneously evaluate patient perception of informa-
tion provided at cancer disclosure and the subsequent
patient satisfaction with information about sexuality and
fertility issues. It highlights that both these issues are dif-
ferent: they are moderately correlated but have distinct
correlates and contributing factors. Indeed, general satis-
faction with medical follow-up was the only common
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Table 1 Satisfaction with fertility- and sexuality-related information in 319 young breast cancer survivors
Total Satisfied with FRI Satisfied with SRI
Continuous data Mean ± SD Mean ± SD P value Mean ± SD P value
Frequency data n (% column) n (% row) n (% row)
At baseline (M0)
Age, years 36.7 ± 3.7 36.7 ± 3.7 0.658 36.7 ± 3.5 0.798
French as mother-language 0.615 0.901
No 17 (5.3) 8 (47.1) 7 (41.2)
Yes 302 (94.7) 161 (53.3) 129 (42.7)
Living as a couple or having regular partner 0.152 0.126
No 41 (12.9) 26 (63.4) 22 (53.7)
Yes 278 (87.1) 143 (51.4) 114 (41.0)
Level of education 0.977 0.086
Lower than high school graduate 103 (32.3) 54 (52.4) 53 (51.5)
High school graduate 60 (18.8) 31 (51.7) 25 (41.7)
Greater than high school graduate 137 (42.9) 73 (53.3) 51 (37.2)
Missing values 19 (6.0)
Employed 0.251 0.050
No 55 (17.2) 33 (60.0) 30 (54.5)
Yes 264 (82.8) 136 (51.5) 106 (40.2)
Having children 0.446 0.911
None 50 (15.7) 29 (58.0) 21 (42.0)
One or more 259 (81.2) 135 (52.1) 111 (42.9)
Missing values 10 (3.1)
Place of residence 0.858 0.680
Rural 38 (11.9) 21 (55.3) 18 (47.4)
<200,000 inhabitants 99 (31.0) 54 (54.5) 44 (44.4)
≥200,000 inhabitants 182 (57.1) 94 (51.6) 74 (40.7)
Had opportunity to ask questions at cancer disclosure 0.002 0.041
No 56 (17.6) 19 (33.9) 17 (30.4)
Yes 263 (82.4) 150 (57.0) 119 (45.2)
Received information about disease at cancer disclosure 0.124 0.006
No 89 (27.9) 41 (46.1) 27 (30.3)
Yes 230 (72.1) 128 (55.7) 109 (47.4)
Satisfied with information about disease at cancer disclosure 0.035 0.004
No 123 (38.6) 56 (45.5) 40 (32.5)
Yes 196 (61.4) 113 (57.7) 96 (49.0)
At 10 month after diagnosis (M10): medical characteristics
Tumor stage 0.960 0.349
Stage 0 36 (11.3) 19 (52.8) 16 (44.4)
Stage I 89 (27.9) 47 (52.8) 36 (40.4)
Stage II 145 (45.5) 79 (54.5) 63 (43.4)
Stage III 44 (13.8) 22 (50.0) 21 (47.7)
Unknown 5 (1.6) 2 (40.0) 0 (0.0)
Breast surgery 0.216 0.250
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Table 1 Satisfaction with fertility- and sexuality-related information in 319 young breast cancer survivors (Continued)
Mastectomy 121 (37.9) 59 (48.8) 57 (47.1)
Tumorectomy 195 (61.1) 109 (55.9) 71 (40.5)
Missing values 3 (0.9)
Chemotherapy 0.769 0.752
No 70 (21.9) 36 (51.4) 31 (44.3)
Yes 249 (78.1) 133 (53.4) 105 (42.2)
FEC100 chemotherapy regimen 0.126 0.430
No 142 (44.5) 82 (57.7) 64 (45.1)
Yes 177 (55.5) 87 (49.2) 72 (40.7)
Radiotherapy 0.696 0.206
No 32 (10.0) 18 (56.3) 17 (53.1)
Yes 287 (90.0) 151 (52.6) 119 (41.5)
Trastuzumab treatment 0.728 0.185
No 259 (81.2) 136 (52.5) 115 (44.4)
Yes 60 (18.8) 33 (55.0) 21 (35.0)
Hormone treatment 0.197 0.094
No 120 (37.6) 58 (48.3) 44 (36.7)
Yes 199 (62.4) 111 (55.8) 92 (46.2)
Family history of breast or ovarian cancer 0.076 0.468
No 225 (70.5) 112 (49.8) 93 (41.3)
Yes 94 (29.5) 57 (60.6) 43 (45.7)
Report of “serious” comorbiditiesa by physician 0.401 0.441
No 273 (85.6) 142 (52.0) 114 (41.8)
Yes 46 (14.4) 27 (58.7) 22 (47.8)
At 10 month after diagnosis (M10): patient questionnaire
Attention and⁄or memory problems 0.232 0.037
No 99 (31.0) 57 (57.6) 51 (51.5)
Yes 201 (63.0) 101 (50.2) 78 (38.8)
Missing values 19 (6.0)
MAC-21 score
Anxious preoccupation subscale 50.0 ± 10.0 48.3 ± 10.3 0.001 48.8 ± 10.4 0.084
Fighting spirit subscale 50.6 ± 10.0 51.9 ± 9.1 0.014 51.4 ± 9.0 0.196
Hopelessness/helplessness subscale 49.2 ± 9.6 48.3 ± 8.6 0.075 49.1 ± 8.6 0.784
At 48 month after diagnosis (M48)
Preserved fertility 0.478 0.429
No 221 (69.3) 120 (54.3) 91 (41.2)
Yes 98 (30.7) 49 (50.0) 45 (45.9)
Satisfied with medical follow-up 0.005 0.007
No 91 (28.5) 37 (40.7) 28 (30.8)
Yes 228 (71.5) 132 (57.9) 108 (47.4)
Score of sexual dysfunction (RSS subscale) 9.5 ± 4.1 9.2 ± 4.2 0.113 9.1 ± 4.2 0.110
FRI fertility-related information; SRI sexuality-related information; SD standard deviation; MAC-21 21-item mental adjustment scale to cancer; RSS relationship and
sexuality scale
aIncluding asthma, diabetes, cardiac problems, HIV infection and/or Hodgkin’s disease
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factor observed (Table 2). As one might expect this fac-
tor to be strongly associated with more specific aspects
of satisfaction, it was systematically adjusted for in all
analyses of more specific satisfaction variables.
In this study, the percentage of women who reported
having had satisfactory discussions on fertility issues
with their healthcare providers is quite similar to the
51.0 % of patients who felt their fertility concerns were
addressed adequately in Partridge et al. [52] in the USA.
However, the rate of satisfaction with information pro-
vided about effects of cancer treatments on sexuality in
our study is below the 52.4 % reported by Ussher et al.
[30] in their study on sexual well-being in Australian BC
survivors of all ages surveyed on average 3.9 years after
diagnosis. One reason may be the lack of specific guide-
lines concerning discussion about sexuality for cancer
patients at the time of the study in France. Our result
confirms the important need to provide detailed and
comprehensive information on sexuality.
Differences regarding predictors associated with FRI
and SRI satisfaction were also observed, particularly con-
cerning patient proactivity when obtaining information
about these two distinct issues. For example, a history of
breast or ovarian cancer among family members of pa-
tients and patients’ active involvement in asking ques-
tions at cancer disclosure were beneficial to obtaining
information on fertility issues. Several physician barriers
to initiating discussions about fertility have been previ-
ously described [53, 54] and may explain why patients
are more active and informed by family to obtain satis-
factory information. Indeed, physician discussion with
their patients (and families) may well be hindered by a
lack of knowledge, resources and communication skills
(lack of adequate vocabulary), or system barriers (the op-
timal time to raise these issues [24] may interfere or
compete with several other issues related to the diagno-
sis, treatment, and prognosis that must be discussed in
the already lengthy initial oncology visit). Instead SRI
satisfaction was associated more with the amount of in-
formation provided spontaneously (i.e. not in response
to a patient question) by the physicians at cancer dis-
closure, suggesting a more passive involvement of pa-
tients regarding sexuality.
Young BC survivors do not obtain adequate FRI and
SRI because the healthcare providers involved tend to
underestimate the importance of this information [7,
30]. In Ussher et al. [30] one patient reported: “It took
4 or 5 times of broaching the subject with my doctors to
finally get a referral to someone who could give me
some advice on how to deal with the vaginal dryness”.
Thewes et al. [29] observed that physicians were slow
to realize that fertility-related information really is an
important issue. Indeed, it has been shown that doctors
are not particularly good at eliciting symptoms related
to treatment morbidity [55]. Clinicians need to be more
aware of symptoms related to treatment morbidity and
need to be more receptive to their patients’ need for
information.
Table 2 Predictors of satisfaction with information about fertility and sexuality in 319 young breast cancer survivors
FRI satisfied SRI satisfied
OR [95 % CI] P value OR [95 % CI] P value
Age at diagnosis, years 1.01 [0.95, 1.08] 0.738 1.01 [0.95, 1.08] 0.713
Living as a couple or having regular partner at diagnosis 0.50 [0.23, 1.10] 0.084 0.48 [0.23, 1.02] 0.057
Education level (versus “less than high school graduate”)
High school graduate 0.94 [0.47, 1.86] 0.849 0.67 [0.35, 1.31] 0.245
Greater than high school graduate 0.88 [0.51, 1.54] 0.664 0.53 [0.31, 0.92] 0.023
Having children at the time of diagnosis 1.00 [0.48, 2.09] 0.996 1.18 [0.58, 2.43] 0.645
Had opportunity to ask questions at cancer disclosure 2.43 [1.27, 4.65] 0.007 NE
Lack of information provided about disease at cancer disclosure NE 0.54 [0.31, 0.93] 0.028
History of attention and/or memory problems at M10 NE 0.58 [0.34, 0.99] 0.045
FEC100 chemotherapy regimen 0.63 [0.39, 1.03] 0.064 NE
Hormone treatment 1.48 [0.88, 2.51] 0.140 1.63 [0.99, 2.70] 0.056
Family history of breast or ovarian cancer 1.72 [1.01, 2.94] 0.046 NE
Score of anxious preoccupation (MAC-21 subscale) at M10 0.97 [0.94, 0.99] 0.006 NE
Fertility preserved at M48 0.80 [0.46, 1.40] 0.440 NE
Score of sexual dysfunction (RSS subscale) at M48 NE 0.96 [0.90, 1.01] 0.138
Satisfied with medical follow-up at M48 2.23 [1.31, 3.79] 0.003 2.03 [1.18, 3.52] 0.011
FRI fertility-related information; SRI sexuality-related information; OR odds ratio (estimated by multivariate binary logistic regression models after applying multiple
imputations); CI confidence interval; NE not entered in the regression model; M10 10 months after diagnosis; M48 48 months after diagnosis; MAC-21 21-item
mental adjustment scale to cancer; RSS relationship and sexuality scale
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As shown in previous research, patients who feel they
are poorly informed are not only dissatisfied with their
care [7, 29, 30, 56], but may also experience a deterioration
in psychosocial wellbeing [7, 23, 27, 28, 31, 34, 35]. The
present study showed that better score of women’s percep-
tion on their body image was associated with greater satis-
faction with both FRI and SRI, although a simple
correlation between two variables measured at the same
time cannot prove the existence of a causal relationship.
Satisfaction with FRI was also negatively associated with
depressive symptoms. Previous studies [31, 34, 35] showed
the significant association between satisfaction with BC in-
formation and patients’ health-related physical and mental
quality of life. In their study including patients and part-
ners across a range of sexual and non-sexual cancers, Perz
et al. [23] also showed that dyadic sexual communication
was a significant predictor of sexual functioning among
women of all ages. Thus, being provided with such infor-
mation can alleviate the anxiety around post-cancer intim-
ate changes, minimize the negative impact on intimate
relationships and enhance health-related quality of life
[56]. Furthermore, in the present study, only the satisfac-
tion with FRI was correlated with women’s overall percep-
tion of their health. For young women with BC, infertility
may perhaps be discussed more with healthcare providers
but may also be more important for patients compared
with sexual dysfunction.
In our study, no socio-demographic characteristic, in-
cluding age and previous children, was associated with
FRI satisfaction, although infertility concerns may be
higher among young women with fewer children [52].
However, for sexuality, young women with a level of
education higher than high school were less likely to be
satisfied with SRI than those with a lower education
level. Furthermore, women who had a sexual partner
were, unsurprisingly, more upset about intimate issues,
since single women who are not sexually active may not
be as aware of the problems associated with intimacy
and the disease [25]. This factor did not reach statistical
significance.
Contrary to previous results [45, 57], the association
between hormone treatment and FRI satisfaction did not
reach statistical significance. Moreover, our multivariate
analysis showed a non-significant difference between
women who had received FEC100 chemotherapy regi-
men and the others, in terms of FRI satisfaction, despite
the known side effects of this regimen on ovarian func-
tion [10].
Some of the factors reducing the probability of being
satisfied with information provided among these women
may well be beyond the scope of medical treatment, to the
extent that they are related to psychosocial vulnerability
[5]. Indeed, our analyses highlight that feelings of anxiety
were associated with poor FRI satisfaction. Anxious
preoccupation in a young woman coping with BC may
stem from not knowing if she will still be able to have a
child. Four years after diagnosis, most of the women in
our study were over 40 years of age, and had received ag-
gressive BC treatment, increasing the risk of fertility loss
due to premature ovarian aging [10]. Having a history of
attention and/or memory problems was also associated
with poor SRI satisfaction, showing the inability of woman
with cognitive impairment to retain information about
sexual health, particularly information passively obtained
(i.e. information provided spontaneously by the doctor,
not as a result of patient questions) [40].
Some limitations of our study have to be acknowl-
edged. No open-ended questions about FRI/SRI were
included on the one hand, and health literacy has not
been assessed, on the other. Hence issues regarding the
kinds, nature, quality, content and impact of the infor-
mation (that patients have accessed or understood)
have not been addressed [56]. Participants in this study
might also not recall all the information previously
given (at diagnosis for example). Thus, their responses
may have been influenced by recall bias. Furthermore,
satisfaction with FRI and SRI was assessed at a single
time point (M48). Only patients with irregular or ab-
sent menstrual periods after BC had been interrogated
at M16 about provision of FRI before the start of treat-
ment. Among the 179 women affected, those who re-
ported they had received this information at M16 were
more likely (P = 0.002) to be satisfied with FRI at M48
(60.1 %) than the others (40.3 %). This may offer some
additional validity to the M48 assessment of satisfac-
tion with FRI. A further limitation was that as data
about satisfaction was collected through telephone in-
terviews, the possibility of social desirability bias can-
not be excluded. Moreover no FRI or SRI satisfaction
measure was available for patients lost to follow-up
4 years after diagnosis. However, the effect of such lim-
itations might have been to overestimate rather than
underestimate satisfaction, if we hypothesize that social
desirability might increase reported satisfaction with
care and dropouts might be more severe patients with
higher risk of side effects and dissatisfaction. The ra-
ther low rate of satisfied women in our study is consist-
ent with previous findings. The main strengths of the
study are its prospective design, a satisfactory response
rate, and a regionally representative sample of young
French women with BC. Because of regional recruit-
ment, it was not possible to document what kinds of
information were routinely provided to these women,
but it seems that the general increase in the provision
of BC information over the 2005–2009 study period
was still not enough to meet the information needs of
young BC survivors regarding the issues of fertility and
sexuality.
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Conclusions
Despite a year-on-year general increase in information
provided at cancer disclosure, nearly half of the young
French 4-year breast cancer survivors in this study were
not satisfied with the information provided about fertil-
ity. More alarmingly, a majority of these women had
wished for more information on sexuality than they in
fact received. More active involvement of patients, in the
form of asking questions, was found to be beneficial to
obtaining more information on fertility but not on sexu-
ality. Encouraging patients to ask questions more often,
through the use of question prompt lists for example
[58], and providing more systematic standardized infor-
mation could improve communication between care-
givers and young breast cancer survivors, and address
specific patient needs regarding fertility- and sexuality-
related information. The training of health professionals
on sexual issues and intimacy is also required to ad-
equately and comprehensively advise couples.
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